常用名：XY028-140

产品描述：

XY028-140 is a selective CDK4/CDK6 degrade and inhibits both CDK4/6 expression and activity in cancer cells. XY028-140 is a PROTAC connected by ligands for Cereblon and CDK.

体外活性 In A375 melanoma and T47D breast cancer cells, XY028-140(0.3 or 1 µΜ for 24h) inhibited both CDK4/6 expression and CDK4/6 activity. In T47D breast cancer cells, XY028-140(0.03, 0.1, 0.3, 1, or 3 µΜ for 11d) inhibited cancer cell proliferation in breast cancer cells[1].

别名 XY028-140

分子量 760.8

分子式 C39H40N10O7

CAS No. 2229974-83-6

存储

Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度

DMSO: 5 mg/mL (6.57 mM), Sonication and heating to 60℃ are recommended.

PROteolysis TArgeting Chimeras (PROTACs) 通过将靶蛋白和 E3 连接酶结合起来，从而“劫持”细胞的泛素-蛋白酶体系统（UPS）来实现蛋白质的降解。由于 PROTACs 只需具有高选择性地结合其靶标（而不是抑制靶蛋白的酶活性），目前有许多努力将先前无效的抑制剂分子改造为 PROTACs，用作下一代药物。

产地：西安

用途：科研！

厂家：西安齐岳生物科技有限公司

温馨提示：仅用于科研，不能用于人体实验！

相关产品：  

Thalidomide-O-PEG5-azide

Thalidomide-O-PEG6-azide

Thalidomide-O-PEG1-Propargyl

Thalidomide-O-PEG2-Propargyl

Thalidomide-O-PEG3-Propargyl

Thalidomide-O-PEG4-Propargyl